Cor Vasa 2004, 45(3):129-131

Cytomegalovirus disease in heart transplant recipients

Mariana Podzimková*, Ivan Málek, Markéta Hegarová, Lenka Hošková
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Cytomegalovirus (CMV) is a major pathogen occurring in patients after solid organ transplantation and continues to pose a serious problem of transplant medicine. In addition to establishing correct diagnosis and initiation of adequate therapy, the issue of preventive ganciclovir administration has not been settled conclusively. CMV disease can follow completely different courses, as documented by the two case reports described below. Every effort is now being made to reach consensus over prevention. Ganciclovir administration is indicated in selected patients at increased risk for developing overt CMV disease.

Keywords: Heart transplantation; Cytomegalovirus; Ganciclovir

Published: March 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podzimková M, Málek I, Hegarová M, Hošková L. Cytomegalovirus disease in heart transplant recipients. Cor Vasa. 2004;45(3):129-131.
Download citation




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.